Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin
Condition(s):Spontaneous Bacterial PeritonitisLast Updated:January 31, 2024Completed
Hide Studies Not Open or Pending
Condition(s):Spontaneous Bacterial PeritonitisLast Updated:January 31, 2024Completed
Condition(s):Uncomplicated Urinary Tract InfectionsLast Updated:January 12, 2021Completed
Condition(s):Bronchiectasis; Pulmonary Disease, Chronic ObstructiveLast Updated:December 19, 2018Completed
Condition(s):Leukemia; Acute Myelogenous Leukemia; Acute Myeloid LeukemiaLast Updated:August 5, 2022Terminated
Condition(s):Inhalational AnthraxLast Updated:April 16, 2019Completed
Condition(s):Metastatic Pancreatic Ductal AdenocarcinomaLast Updated:August 24, 2020Unknown status
Condition(s):Alcoholic Hepatitis; Alcoholic CirrhosisLast Updated:January 19, 2017Completed
Condition(s):HealthyLast Updated:June 9, 2021Completed
Condition(s):Urinary Tract Infection; PyelonephritisLast Updated:September 5, 2023Completed
Condition(s):RhinoscleromaLast Updated:February 13, 2018Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.